fik lige nyheden om J-code og det mener nogen er en ret afgørende booster for salget i Arzerra. Formuleringen "Oncologists typically use the medication to treat chronic lymphocytic leukemia in adults
-
fik lige nyheden om J-code og det mener nogen er en ret afgørende booster for salget i Arzerra. Formuleringen "Oncologists typically use the medication to treat chronic lymphocytic leukemia in adults who have not responded satisfactorily to fludarabine or alemtuzumab"- er lidt interessant fordi den åbner døren en lille smule på klem for at man kan ordinere arzerra i andet end labellen. Uanset hvad vil J-code faktoren først være at registrerer i næste kvartal og ikke i dette der afrapporteres d.3 februar.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind